Functional role of CD40 and its ligand

International Archives of Allergy and Immunology

Volumn 113, Issue 4, 1997, Pages 393-399

  van Kooten, Cees ^a   Banchereau, Jacques ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

Basic science review; CD40; CD40L; Immunology

Indexed keywords

CD40 ANTIGEN; CELL SURFACE RECEPTOR; LIGAND; TUMOR NECROSIS FACTOR RECEPTOR;

DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; IMMUNOREGULATION; MONOCYTE; PRIORITY JOURNAL; REVIEW;

EID: 8544263811     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237614     Document Type: Article

References (47)

1. Smith CA, Farrah T, Goodwin RG: TheTNF receptor superfamily of cellular and viral proteins: Activation, costimulation and death. Cell 1994;76:959-962.
2. Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T, Dash L, Page K, Solari R, Aldcbcrt D, Capron M, Dahindcn C, Bonnefoy JY: CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol 1995;25. 863-865.
3. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE: The CD40 ligand expressed by human B cells costimulates B cells responses. J Immunol 1995; 154:4996-5010.
4. Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Worsen JP, Clark EA: Functional CD40 ligand expressed by human blood dendritic cells is upregulated by CD40 ligation. J Immunol 1996;157:4363-4370.
5. Karpusas M, Hsu YM, Wang JH, Thompson J, Lcderman S, Chess L, Thomas D: 2A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995:3:1031-1039.
6. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D: Heteromultimcric complexes of CD40 ligand arc present on the cell surface of human T lymphocytes. J Biol Chcm 1997:272: 911-915.
7. Graf D, Muller S, Korthauer U, van Kootcn C, Weise C, Kroczek RA: A soluble form ofTRAP (CD40 ligand) is rapidly released after T cell activation. F.urJ Immunol 1995:25:1749-1754.
8. Mazzei GJ, Edgerton MD, Losberger C, Lccoa-net-Henchoz S, Graber P, Duratidy A, Gauchat IF, Bernard A, Allet B, Bonnefoy JY: Recombinant soluble rimeric CD40 ligand is biologically active. J Biol Chern 1995:270:7025-7028.
9. Ludewig B, Henn V, Schroder JM, Graf D, Krozcek RA: Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4 CD45RA T cells with dendritic cells. Eur J Immunol 1996:26: 3137-3143.
10. Black RA, Rauch CT, Kozlosky CJ, Pcschon JJ, Slack JL, Wolfson MF, Castner BI, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schoolcy KA, Gerhardt M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Pat Cerrctti D: A metalloproteinase disintegrin that releases tumour-necrosis factor-ct from cells. Nature 1997;385:729-733.
11. Moss ME, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Lecsnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahcl G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Bccherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997; 385:733-736.
12. Kehry MR: CD40-mcdiatcd signaling in B cells. J Immunol 1996;156:2345-2348.
13. Hu HM, O’Rourke K, Boguski MS, Dixit VM: A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chcm 1994:269:30069-30072.
14. Mosialos G, Birkcnbach M, Yalamanchili R, Van Arsdale T, Ware C, Kieff E: The F.pstein-Barr virus transforming protein LMPI engages signaling proteins for the tumor necrosis factor family. Cell 1995:80:389-399.
15. Xu Y, Cheng G, Baltimore D: Targeted disruption of TRAF3 leads Jo postnatal lethality and defective T-dependent immune responses. Immunity 1996:5:407-415.
16. Rot he M, Sarma V, Dixit VM, Gocddcl DV: TRAF2-mediated activation of NF-z.B by TNF receptor 2 and C'D40. Science 1995:269:1424-1427.
17. Rothe M, Xiong J, Shu MB, Williamson K, Goddard A, Goeddel DV: l-TRAF is a novel TRAF-intcracting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 1996:93:8241-8246.
18. lshida T, Tojo T, Aoki T, Kobayashi N, Ohishi T, Watanabc T, Yamamoto T, Inoue J: TRAF5. a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996;93:9437-9442.
19. Nakano H, Oshima H, Chung W, Williams-Ab-botl L, Ware CF, Yagita H, Okumura K: TRAF5. an activator of NF-xB and putative signal transducer for the lymphotoxin-p receptor. J Biol C'hem 1996:271:14661-14664.
20. lshida T, Mizushima S, Azuma S, Kobayashi N, Tojo T, Suzuki K, Aizawa S, Watanabe T, Mosialos G, Kieff F, Yamamoto T, Inoue J: Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Client 1996;271:28745-28748.
21. Banehcrcau J, Bazan K, Blanchard D, Bricre F, Galizzi IP, Van Kooten C, Liu YJ, Roussel F, Sacland S: The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922.
22. Van Kootcn C, Banchereau J: CD40-CD40 ligand: A multifunctional rcceptor-ligand pair. Adv Immunol 1996:61:1-77.
23. Foy TM, ArufTo A, Bajorath J, Buhlmann JE, Noclle J: Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 1996; 14:591-617.
24. Liu YJ, Malisan F, de Bouteiller O, Gurct C, Le-becque S, Banchereau J, Mills FC, Max EE, Martinez-Valdez H: Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset fo somatic mutation. Immunity 1996;4:241-250.
25. Galibert L, Burdin N, Barthclemv C, Meffre G, Durand I, Garcia E, Garrotte P, Rousset F, Ban-chereau J, Liu YJ: Negative selection of human germinal center B cells by prolonged BCR cross-linking. J Exp Med 1996:183:2075-2085.
26. Rathmell JC, Townsend SE, Xu JC, Flavcll RA, Goodnow CC: Expansion or elimination of B cells in vivo: Dual roles for CD40 and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996;87:319-329.
27. Arpin C, Dcchanet J, Van Kooten C, Merville P, Grouard G, Briere F, Banchereau I, Liu YJ: Generation of memory' B cells and plasma cells in vitro. Science 1995:268:720-722.
28. Stout RD, Suttles J: The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996:17:487-492.
29. Grewal IS, Flavcll RA: A central role ofCD40 ligand in the regulation of CD4 T cell responses. Immunol Today 1996;17:410-414.
30. Flores-Romo L, Bjorck P, Duvert V, Van Kootcn C, Saeland S, Banchereau J: CD40 ligation on human cord blood CD34 hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J Exp Med 1997;185:341-349.
31. Van Essen D, Kikutani II, Gray D: CD40 ligand-transduced co-stimulation of f cells in the development of helper function. Nature 1995; 378:620-623.
32. Blotta MU, Marshall JD, DcKruyff RH, Umet-su DT: Cross-linking of the CD40 ligand on human CD4 T lymphocytes generates a costimulatory signal that up-rcgulates IL-4 synthesis. J Immunol 1996;156:3133-3140.
33. Peng X, Kasran A, Warmerdam PAM, De Boer M, Ceuppens JL: Accessory signaling by CD40 forT cell activation: Induction of Thl and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur J Immunol 1996:26:1621-1627.
34. I lay ward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonncfoy JY, Cosyns M, Weinberg A: Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linkcd immunodeficiency with hvper-lgM. J Immunol 1997;158:977-983.
35. Notarangelo LD, Pcitch MC: CD40Lbase: a de-tabase of CD40L gene mutations causing X-linkcd hyper-IgM syndrome. Immunol Today 1996:17:511-516.
36. Noclle RI: CD40 and its ligand in host defense. Immunity 1996:4:415-419.
37. Chu YW, Marin E, Fuleihan R, Ramcsh N, Rosen FS, Gelta RS, Insel RA: Somatic mutation of human immunoglobulin V genes in the X-linked hyper-IgM syndrome. J Clin Invest 1995;95:1389-1393.
38. Razanajaona D, Van Kooten C, Lebecquc S, Bridon JM, Ho S, Smith S, Callard R, Banchc-rcau J, Brierc F: Somatic mutations in human Ig variable genes correlate with a partially functional CD40-ligand in the X-linked hyper-IgM syndrome. J Immunol 1996;157:1492-1498.
39. Gerritse K, Laman JD, Noclle RJ, Aruffo A, Ledbetter JA, Boersma WJA, Claassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996:93:2499-2504.
40. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janaway CA, Flavcll RA: Requirement for CD40 ligand in costimulation induction. T cell activation, and experimental allergic encephalomyelitis. Science 1996:273:1864-1867.
41. Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995:154:1470-1480.
42. Early GS, Zhao W, Burns CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice. J Immunol 1996;157:3159-3164.
43. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK: Hyperexpression of CD40 ligand by B aad T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996:97:2063-2073.
44. Koshy M, Berger D, Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-837.
45. Yellin MJ, DXgati V, Parkinson G, Han ASY, Szema A, Baum D, Estes D, Szabolzs M, Chess L: Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomeruloncphritides. Arthritis Rheum 1997:40:124-134.
46. Van Kooten C, Gerritisma JSJ, Paape ME, Van Es LA, Banchereau J, Daha MR: Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997; 51:711-721.
47. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Clio HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.